Childress Capital Advisors LLC Has $611,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Childress Capital Advisors LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 4.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,895 shares of the medical research company’s stock after selling 87 shares during the period. Childress Capital Advisors LLC’s holdings in Amgen were worth $611,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Lake Street Private Wealth LLC grew its holdings in Amgen by 30.4% during the 1st quarter. Lake Street Private Wealth LLC now owns 2,173 shares of the medical research company’s stock worth $618,000 after acquiring an additional 507 shares during the last quarter. Kovack Advisors Inc. increased its holdings in Amgen by 23.8% in the first quarter. Kovack Advisors Inc. now owns 3,694 shares of the medical research company’s stock valued at $1,050,000 after purchasing an additional 711 shares during the period. First Trust Direct Indexing L.P. lifted its holdings in Amgen by 13.2% during the 1st quarter. First Trust Direct Indexing L.P. now owns 10,176 shares of the medical research company’s stock worth $2,893,000 after buying an additional 1,184 shares during the period. Core Wealth Partners LLC increased its stake in shares of Amgen by 8.0% in the first quarter. Core Wealth Partners LLC now owns 1,053 shares of the medical research company’s stock valued at $299,000 after buying an additional 78 shares during the period. Finally, Spinnaker Investment Group LLC lifted its stake in shares of Amgen by 1.6% in the first quarter. Spinnaker Investment Group LLC now owns 2,858 shares of the medical research company’s stock worth $813,000 after acquiring an additional 45 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $316.00 on Wednesday. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The company has a fifty day moving average price of $325.02 and a 200-day moving average price of $314.78. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85. The firm has a market cap of $169.51 billion, a price-to-earnings ratio of 45.14, a PEG ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter last year, the business posted $5.00 EPS. The company’s quarterly revenue was up 20.1% on a year-over-year basis. As a group, equities research analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 2.85%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. TD Cowen upped their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Sanford C. Bernstein assumed coverage on Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price on the stock. Finally, Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and lifted their target price for the stock from $320.00 to $333.00 in a report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.